Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy.
Martina PaolettiChiara BiniAndrea MarcellusiFrancesco Saverio MenniniPublished in: Clinical drug investigation (2024)
The analysis demonstrated that, compared with chemotherapy, pembrolizumab is more cost effective in Italy as a first-line treatment in patients with metastatic squamous or non-squamous NSCLC and, if compared with watchful waiting, as adjuvant treatment in patients with stage III melanoma. The present analysis suggested that pembrolizumab use could lead to important health benefits for patients while offsetting a portion of cancer care costs.
Keyphrases
- advanced non small cell lung cancer
- healthcare
- small cell lung cancer
- public health
- end stage renal disease
- high grade
- mental health
- squamous cell carcinoma
- newly diagnosed
- ejection fraction
- chronic kidney disease
- early stage
- low grade
- type diabetes
- prognostic factors
- adipose tissue
- metabolic syndrome
- radiation therapy
- combination therapy
- health promotion
- risk assessment
- skin cancer
- patient reported outcomes
- epidermal growth factor receptor
- locally advanced
- patient reported
- brain metastases